The Effects of Remimazolam versus Propofol on Endovascular Thrombectomy for Acute Ischemic Stroke: Study Protocol for a Randomized Controlled Trial.

IF 2.6 Q2 PERIPHERAL VASCULAR DISEASE

Vascular Health and Risk Management Pub Date : 2024-12-03 eCollection Date: 2024-01-01 DOI:10.2147/VHRM.S486834

Lijuan Fu, Rui Zhou, Wencai Jiang, Lan Lan, Xuemeng Chen, Yuansheng Cao, Leqiang Xia, Yukai Zhou, Jia Han, Dan Zhou, Xianjie Zhang

{"title":"The Effects of Remimazolam versus Propofol on Endovascular Thrombectomy for Acute Ischemic Stroke: Study Protocol for a Randomized Controlled Trial.","authors":"Lijuan Fu, Rui Zhou, Wencai Jiang, Lan Lan, Xuemeng Chen, Yuansheng Cao, Leqiang Xia, Yukai Zhou, Jia Han, Dan Zhou, Xianjie Zhang","doi":"10.2147/VHRM.S486834","DOIUrl":null,"url":null,"abstract":"Background: While general anesthesia has been widely used in endovascular thrombectomy for acute ischemic stroke (AIS), the optimal anesthesia medication for hemodynamic management remains unclear.Purpose: To compare the effects of remimazolam and propofol on endovascular thrombectomy for AIS.Methods: This study is a single-center, double-blind and randomized controlled trial. Eligible patients will be randomly allocated into the remimazolam group and propofol group. Remimazolam and propofol will be administered to induce and maintain anesthesia respectively. The primary outcome is the incidence of intraoperative hypotension. The secondary outcomes include frequency of hypotension, the largest difference value of mean arterial pressure (MAP), dosage of vasopressors, extubation time, operation time, modified thrombolysis in cerebral infarction (mTICI) level, National Institutes of Health Stroke Scale (NIHSS) score and modified Rankin scale (mRS) score.Conclusion: This study evaluates the influences of remimazolam versus propofol on endovascular therapy for AIS patients. Results of this study are expected to provide more evidence of the choice of anesthetics in this kind of operation.Trial registration: This study has been registered at the Chinese Clinical Trial Registry (ChiCTR2300076880).","PeriodicalId":23597,"journal":{"name":"Vascular Health and Risk Management","volume":"20 ","pages":"533-539"},"PeriodicalIF":2.6000,"publicationDate":"2024-12-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11625192/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Vascular Health and Risk Management","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2147/VHRM.S486834","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}

引用次数: 0

Abstract

Background: While general anesthesia has been widely used in endovascular thrombectomy for acute ischemic stroke (AIS), the optimal anesthesia medication for hemodynamic management remains unclear.

Purpose: To compare the effects of remimazolam and propofol on endovascular thrombectomy for AIS.

Methods: This study is a single-center, double-blind and randomized controlled trial. Eligible patients will be randomly allocated into the remimazolam group and propofol group. Remimazolam and propofol will be administered to induce and maintain anesthesia respectively. The primary outcome is the incidence of intraoperative hypotension. The secondary outcomes include frequency of hypotension, the largest difference value of mean arterial pressure (MAP), dosage of vasopressors, extubation time, operation time, modified thrombolysis in cerebral infarction (mTICI) level, National Institutes of Health Stroke Scale (NIHSS) score and modified Rankin scale (mRS) score.

Conclusion: This study evaluates the influences of remimazolam versus propofol on endovascular therapy for AIS patients. Results of this study are expected to provide more evidence of the choice of anesthetics in this kind of operation.

Trial registration: This study has been registered at the Chinese Clinical Trial Registry (ChiCTR2300076880).

查看原文本刊更多论文

雷马唑仑与异丙酚对急性缺血性卒中血管内血栓切除术的影响：一项随机对照试验研究方案。

背景：虽然全身麻醉已广泛应用于急性缺血性卒中（AIS）的血管内取栓术，但血流动力学管理的最佳麻醉药物仍不清楚。目的：比较雷马唑仑与异丙酚在AIS血管内取栓术中的作用。方法：采用单中心、双盲、随机对照试验。符合条件的患者将被随机分配到雷马唑仑组和异丙酚组。雷马唑仑和异丙酚分别用于诱导和维持麻醉。主要观察指标是术中低血压的发生率。次要结局包括低血压发生频率、平均动脉压最大差值（MAP）、血管加压剂用量、拔管时间、手术时间、改良脑梗死溶栓（mTICI）水平、美国国立卫生研究院卒中量表（NIHSS）评分和改良Rankin量表（mRS）评分。结论：本研究评价了雷马唑仑与异丙酚对AIS患者血管内治疗的影响。本研究结果有望为该类手术中麻醉药的选择提供更多的依据。试验注册：本研究已在中国临床试验注册中心注册（ChiCTR2300076880）。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Vascular Health and Risk Management PERIPHERAL VASCULAR DISEASE-

CiteScore

4.20

自引率

3.40%

发文量

109

审稿时长

16 weeks

期刊介绍： An international, peer-reviewed journal of therapeutics and risk management, focusing on concise rapid reporting of clinical studies on the processes involved in the maintenance of vascular health; the monitoring, prevention, and treatment of vascular disease and its sequelae; and the involvement of metabolic disorders, particularly diabetes. In addition, the journal will also seek to define drug usage in terms of ultimate uptake and acceptance by the patient and healthcare professional.